Erasca (ERAS) vs Grifols S.A. (GRFS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Erasca (ERAS) has outperformed Grifols S.A. (GRFS) over the past year, gaining 536.2% versus a loss of 23.1%. Over five years, ERAS leads with a -13.1% price change compared with -47.9% for GRFS. Erasca is the larger company by market cap ($5.41 billion vs $5.04 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ERAS | GRFS |
|---|---|---|
| Share price | $15.46 | $7.41 |
| Market cap | $5.41B | $5.04B |
| 1-day change | +9.49% | -1.20% |
| YTD return | +315.59% | -20.75% |
| 1-year return | +536.21% | -23.05% |
| 5-year return | -13.15% | -47.89% |
| P/E ratio (TTM) | — | 9.62 |
| Forward P/E | — | 5.14 |
| EPS (TTM) | $-0.95 | $0.77 |
| Dividend yield | 0.00% | 1.41% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-124.55M | — |
| 52-week high | $24.28 | $9.90 |
| 52-week low | $2.11 | $6.96 |
| Distance from 52-week high | -36.33% | -25.15% |
| Analyst consensus | none | none |
| Avg. price target upside | +55.95% | +46.69% |
| Average volume | 4.37M | 580.72K |
| Shares outstanding | 349.76M | 258.22M |
| Employees | 103 | 25,258 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ERAS has outperformed GRFS by 559.3 percentage points over the past year.
- Grifols S.A. offers a meaningfully higher dividend yield (1.41% vs 0.00%).
About Erasca
ERAS stock →Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees
About Grifols S.A.
GRFS stock →Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.
Health Care · Biotechnology: Pharmaceutical Preparations · 25,258 employees
ERAS vs GRFS FAQ
Which is bigger, Erasca or Grifols S.A.?
Erasca (ERAS) is larger, with a market capitalization of $5.41B compared with $5.04B for Grifols S.A. (GRFS).
Which stock has performed better over the past year, ERAS or GRFS?
ERAS returned +536.21% over the past 12 months, compared with -23.05% for GRFS (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Erasca or Grifols S.A.?
Grifols S.A. pays a dividend yielding 1.41%, while Erasca does not currently pay a regular dividend.
Are Erasca and Grifols S.A. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.